$1,318.00
This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Glaucoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Eye drops
10 Oral medications
10 Intraocular implants
12 EPIDEMIOLOGY
16 MARKETED DRUGS
23 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 iDose-Travoprost for Glaucoma (September 7, 2022)
30 Rhopressa for Glaucoma (October 12, 2021)
31 PDP-716 for Glaucoma (May 14, 2021)
33 KEY UPCOMING EVENTS
34 KEY REGULATORY EVENTS
34 Omlonti Joins Growing Ophthalmology Pharmacopoeia
34 Contract Manufacturer Trips Up Santen/Ube Eye Drug
35 PROBABILITY OF SUCCESS
36 LICENSING AND ASSET ACQUISITION DEALS
36 Alcon Buys Aerie, Reaffirming Commitment To Pharma Space
36 Minute Insight: AbbVie Bets Big On Glaucoma Market With iSTAR Purchase Deal
36 Akorn Sharpens Focus As It Divests Ophthalmic Brands
37 Sun Spinout Finalizes Ophthalmology, Antibody Licensing Deals
37 Alcon Sees Big Opportunity In Glaucoma Surgery; Buys Ivantis For $475M
39 REVENUE OPPORTUNITY
42 CLINICAL TRIAL LANDSCAPE
43 Sponsors by status
44 Sponsors by phase
46 BIBLIOGRAPHY
47 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of glaucoma, 2021–30
23 Figure 2: Overview of pipeline drugs for glaucoma in the US
23 Figure 3: Pipeline drugs for glaucoma, by company
24 Figure 4: Pipeline drugs for glaucoma, by drug type
24 Figure 5: Pipeline drugs for glaucoma, by classification
32 Figure 6: PDP-716 for Glaucoma (May 14, 2021): Phase III – CLR_16_33
33 Figure 7: Key upcoming events in glaucoma
35 Figure 8: Probability of success in the glaucoma/ocular hypertension (ophthalmology) pipeline
42 Figure 9: Clinical trials in glaucoma
42 Figure 10: Top 10 drugs for clinical trials in glaucoma
43 Figure 11: Top 10 companies for clinical trials in glaucoma
43 Figure 12: Trial locations in glaucoma
44 Figure 13: Glaucoma trials status
45 Figure 14: Glaucoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of glaucoma, 2021–30
15 Table 2: Prevalence proportions in glaucoma, 2021–30
17 Table 3: Marketed drugs for glaucoma
25 Table 4: Pipeline drugs for glaucoma in the US
29 Table 5: iDose-Travoprost for Glaucoma (September 7, 2022)
30 Table 6: Rhopressa for Glaucoma (October 12, 2021)
31 Table 7: PDP-716 for Glaucoma (May 14, 2021)
40 Table 8: Historical global sales, by drug ($m), 2017–21
41 Table 9: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!